CAMRF (Camurus AB) Additional Paid-In Capital : $316.9 Mil(As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Camurus AB Additional Paid-In Capital?

Camurus AB's quarterly additional paid-in capital increased from Dec. 2023 ($199.1 Mil) to Mar. 2024 ($299.1 Mil) and increased from Mar. 2024 ($299.1 Mil) to Jun. 2024 ($316.9 Mil).

Camurus AB's annual additional paid-in capital declined from Dec. 2021 ($207.6 Mil) to Dec. 2022 ($190.2 Mil) but then increased from Dec. 2022 ($190.2 Mil) to Dec. 2023 ($199.1 Mil).

Camurus AB Additional Paid-In Capital Historical Data

The historical data trend for Camurus AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Additional Paid-In Capital Chart

Camurus AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

149.77

214.88

207.64

190.18

199.12

Camurus AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial															185.43	182.18	199.12	299.08	316.87

Camurus AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Camurus AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Camurus AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Camurus AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CAMX:Sweden CAMXs:UK 0RD1:UK 7CA:Germany

Address

Ideon Science Park, Lund, SWE, SE-223 70

Website

https://www.camurus.com

Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.